Key Takeaways
- Double‑digit revenue and EBITDA growth (+14% revenue, +19% EBITDA) in 2025.
- Eight new pharma products integrated in just 18 months, reinforcing the specialty‑pharma portfolio.
- CDMO expansion in the United States adds early‑development capabilities.
- B‑Corp certification underscores ESTEVE’s ESG leadership.
- Targeted acquisitions (Infusion Business Unit of TerSera, Regis Technologies) accelerate inorganic growth.
- Planned €1 billion revenue by 2027 driven by organic and inorganic initiatives.
Strategic Growth Overview ESTEVE presented its 2025 results on May 4, 2026, emphasizing a year of strong execution that delivered double‑digit net‑revenue growth (€828 million, +14% at constant exchange rate) and a 19% increase in EBITDA to €151 million. The performance reflects the effectiveness of a dual‑engine model that combines inorganic expansion in both the pharma and CDMO segments with a disciplined focus on specialty medicines. The impressive margins and growth rates demonstrate that the strategy not only sustains profitability but also supports long‑term shareholder value.
Portfolio Expansion in Pharma
Throughout 2025 ESTEVE advanced its long‑term roadmap by adding three highly specialized oncology and endocrinology medicines to its already robust portfolio. In March 2026 the company finalized the acquisition of the Infusion Business Unit of TerSera, a US‑based pharma company that contributed two additional flagship products. This transaction marks the eighth new product integrated in less than 18 months, significantly widening the company’s reach into underserved patient populations and strengthening its presence in key therapeutic areas.
CDMO Expansion and Acquisitions
Parallel to its pharma activities, ESTEVE reinforced its CDMO business by purchasing Regis Technologies in the United States, a deal that introduced early‑phase development capabilities and positioned ESTEVE at the heart of the world’s largest pharmaceutical market. This acquisition, together with the integration of the TerSera infusion unit, expands the CDMO network to include facilities in Spain, Mexico, China, and the US, thereby creating a seamless offering from early development through commercial manufacturing. The enhanced footprint enables partners to accelerate product pipelines while leveraging ESTEVE’s proven integration expertise.
Financial Highlights and Margin Strength
The 2025 financial results reveal that both the Pharma and CDMO divisions contributed similarly to revenue growth, each aligning with its respective roadmap. EBITDA reached €151 million, delivering an 18% EBITDA margin on revenue—a testament to the strength of ESTEVE’s diversified business model. Revenue growth was consistent across segments, supporting a stable margin despite increased investment in product process development and technology (€49 million in 2025, a 7% increase year‑over‑year). Capital expenditure of €104 million primarily funded new industrial sites in Spain and China, underscoring the commitment to scalable manufacturing capacity.
Capital Expenditure and Future Investment
Over the past two years ESTEVE has invested more than €500 million to enhance its patient‑focused pharma portfolio and expand CDMO capabilities. In 2025 alone, €49 million was earmarked for process development and technology upgrades, while €104 million funded the construction of new facilities in strategic locations. Looking ahead, the company plans to continue allocating resources toward both organic innovation and strategic acquisitions, aiming to reach €1 billion in net revenue by 2027. This growth trajectory is underpinned by a clear vision of expanding the Highly Specialized pharma pipeline and deepening international market penetration in the EU and the United States.
ESG Leadership and B‑Corp Certification
Sustainability and responsible governance remain central pillars of ESTEVE’s corporate philosophy. In 2025 the company achieved B‑Corp certification, formally recognizing that its operations meet rigorous standards of social and environmental performance, transparency, and accountability. ESG criteria are now embedded across all decision‑making processes, with initiatives such as renewable electricity sourcing, water‑conservation programs, and waste‑reduction strategies driving measurable environmental improvements. Socially, ESTEVE strengthened its community impact by partnering with patient organizations, supporting healthcare institutions, and funding projects that reached hundreds of thousands of individuals worldwide.
Workforce, Culture, and Employee Engagement
ESTEVE employs over 2,200 professionals representing 35 nationalities, reflecting its truly global character. The company reported a record employee‑engagement score of 87% in its 2025 worldwide survey, highlighting a vibrant culture built on the tenets of “People Matter,” transparency, and accountability. This high level of engagement is attributed to continuous investment in talent development, inclusive leadership, and a work environment that aligns personal purpose with corporate mission.
Future Outlook and Projections
Looking toward 2027, ESTEVE anticipates surpassing the €1 billion revenue threshold, driven by a blend of organic growth and accretive acquisitions across both Pharma and CDMO segments. The company’s roadmap emphasizes continued expansion of its highly specialized medicine lineup, deeper penetration into emerging markets, and the scaling of CDMO services that now encompass early‑development, manufacturing, and commercial supply. By maintaining disciplined financial management, robust ESG commitments, and a talent‑centric culture, ESTEVE is positioned to deliver sustained value to patients, partners, and investors alike.
Conclusion
In 2025 ESTEVE demonstrated how strategic acquisitions, disciplined capital allocation, and a steadfast commitment to ESG principles can translate into tangible financial performance and meaningful societal impact. The successful integration of eight new products in less than a year and the strengthening of CDMO capabilities illustrate a proactive growth engine that is poised to accelerate toward its 2027 revenue target. As the company continues to innovate in specialty pharma and expand its global manufacturing footprint, it remains anchored by its purpose—improving lives together—while delivering profitable growth for all stakeholders.